HUP0003745A2 - Eljárások és készítmények tumorspecifikus citotoxicitás indukálására - Google Patents

Eljárások és készítmények tumorspecifikus citotoxicitás indukálására

Info

Publication number
HUP0003745A2
HUP0003745A2 HU0003745A HUP0003745A HUP0003745A2 HU P0003745 A2 HUP0003745 A2 HU P0003745A2 HU 0003745 A HU0003745 A HU 0003745A HU P0003745 A HUP0003745 A HU P0003745A HU P0003745 A2 HUP0003745 A2 HU P0003745A2
Authority
HU
Hungary
Prior art keywords
compositions
methods
specific cytotoxicity
inducing tumor
tumor cells
Prior art date
Application number
HU0003745A
Other languages
English (en)
Inventor
Suhail Ayesh
Abraham Hochberg
Original Assignee
Yissum Research Development Company Of The Hebrew University Of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Company Of The Hebrew University Of Jerusalem filed Critical Yissum Research Development Company Of The Hebrew University Of Jerusalem
Publication of HUP0003745A2 publication Critical patent/HUP0003745A2/hu
Publication of HUP0003745A3 publication Critical patent/HUP0003745A3/hu
Publication of HU228470B1 publication Critical patent/HU228470B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány heterológ gének, különösen citotoxikus termékeket kódológének specifikus expressziójára vonatkozik tumorsejtekben. Azexpressziót úgy hajtják végre, hogy egy citotoxikus génterméket kódolóheterológ szekvenciát és egy ahhoz működőképesen kapcsoltszabályozószekvenciát tartalmazó polinukleotidot visznek be atumorsejtekbe, mely szabályozószekvencia egy tumorsejtben specifikusanexpresszálódó, genomiális imprintingen átesett génből származik, vagyaz IGF-1 promoter. Továbbá a találmány tárgyát képezi a fentipolinukleotidot tartalmazó vektor is. A találmány a rákosmegbetegedések kezelésére alkalmazható. Ó
HU0003745A 1997-10-03 1998-10-04 Methods and compositions for inducing tumor-specific cytotoxicity HU228470B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94360897A 1997-10-03 1997-10-03
PCT/IL1998/000486 WO1999018195A2 (en) 1997-10-03 1998-10-04 Methods and compositions for inducing tumor-specific cytotoxicity

Publications (3)

Publication Number Publication Date
HUP0003745A2 true HUP0003745A2 (hu) 2001-02-28
HUP0003745A3 HUP0003745A3 (en) 2002-04-29
HU228470B1 HU228470B1 (en) 2013-03-28

Family

ID=25479934

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003745A HU228470B1 (en) 1997-10-03 1998-10-04 Methods and compositions for inducing tumor-specific cytotoxicity

Country Status (17)

Country Link
US (2) US6087164A (hu)
EP (1) EP1019499B1 (hu)
JP (3) JP5153031B2 (hu)
KR (1) KR100524262B1 (hu)
CN (1) CN1229496C (hu)
AT (1) ATE407948T1 (hu)
AU (1) AU755774B2 (hu)
BR (1) BR9812717B1 (hu)
CA (1) CA2308124C (hu)
CZ (2) CZ294694B6 (hu)
DE (1) DE69840001D1 (hu)
HU (1) HU228470B1 (hu)
IL (1) IL135430A0 (hu)
NO (2) NO328470B1 (hu)
PL (1) PL339949A1 (hu)
RU (1) RU2214280C2 (hu)
WO (1) WO1999018195A2 (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006220A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of insulin-like growth factor 2 expression
US7041654B2 (en) 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
WO2000061804A1 (en) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
DE19928342A1 (de) * 1999-06-21 2000-12-28 Deutsches Krebsforsch Vektoren zur gentherapeutischen Tumorbehandlung
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20040209263A1 (en) * 2000-12-07 2004-10-21 Clawson Gary A. Selection of catalytic nucleic acids targeted to infectious agents
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20040005567A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of cyclin-dependent kinase 4 expression
WO2003102186A1 (fr) * 2002-05-31 2003-12-11 Medinet Co., Ltd. Adn induisant l'expression specifique des cellules cancereuses et vecteur d'expression specifique des cellules cancereuses
US20040180844A1 (en) * 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
US20040219099A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Method for the treatment of tumors
US20040220085A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Compositions for nucleic acid delivery
US7482156B2 (en) * 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
US7063947B2 (en) * 2004-04-08 2006-06-20 Promogen, Inc. System for producing synthetic promoters
US7429482B2 (en) * 2005-01-13 2008-09-30 United States Of America As Represented By The Department Of Veterans Affairs Screening tools for discovery of novel anabolic agents
CN101273130B (zh) 2005-07-07 2012-05-30 耶路撒冷希伯来大学伊森姆研究发展公司 用于下调h19的核酸物质及其使用方法
JP2009508516A (ja) 2005-09-22 2009-03-05 イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム 核酸構築物、薬剤組成物、及び癌治療のためのその使用方法
WO2008087641A2 (en) * 2007-01-16 2008-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis
JP2010540534A (ja) 2007-09-28 2010-12-24 イントレキソン コーポレーション 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用
AU2008315409B2 (en) 2007-10-25 2013-10-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Constructs containing multiple expression cassettes for cancer therapy
US20110104656A1 (en) * 2008-07-02 2011-05-05 Otsuka Pharmaceutical Factory, Inc. Artificial kidney precursor and process for production thereof
US8492133B2 (en) 2009-01-20 2013-07-23 Ramot At Tel Aviv University, Ltd. MIR-21 promoter driven targeted cancer therapy
EA016223B1 (ru) * 2009-10-07 2012-03-30 Учреждение Российской Академии Наук Институт Молекулярной Генетики Ран Способ и генная конструкция для высокоспецифичного ингибирования нежелательного роста клеток
SG10201909209RA (en) 2015-05-05 2019-11-28 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Nucleic acid-cationic polymer compositions and methods of making and using the same
AU2019261982A1 (en) * 2018-04-30 2020-10-15 Amicus Therapeutics, Inc. Gene therapy constructs and methods of use
CN110714075B (zh) * 2018-07-13 2024-05-03 立森印迹诊断技术（无锡）有限公司 一种用于检测肺肿瘤良恶性程度的分级模型及其应用
CN111206093A (zh) * 2018-11-21 2020-05-29 立森印迹诊断技术（无锡）有限公司 一种用于检测浸润性膀胱癌的标志物及其应用
CN109609505A (zh) * 2019-01-14 2019-04-12 中国科学院成都生物研究所 一种体内筛选的剪切rna的锤头状核酶

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2699191B1 (fr) * 1992-12-16 1995-02-10 Univ Paris Curie Nouveaux vecteurs rétroviraux, lignées cellulaires les contenant, et leur utilisation dans le traitement des tumeurs.
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
IL108879A (en) * 1994-03-07 2000-08-31 Yissum Res Dev Co Diagnostic assay for malignancies using the H19 gene and kit
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
FR2725213B1 (fr) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique

Also Published As

Publication number Publication date
CN1280616A (zh) 2001-01-17
CZ294694B6 (cs) 2005-02-16
CN1229496C (zh) 2005-11-30
WO1999018195A3 (en) 1999-08-12
HU228470B1 (en) 2013-03-28
RU2214280C2 (ru) 2003-10-20
NO331723B1 (no) 2012-03-05
ATE407948T1 (de) 2008-09-15
CZ294941B6 (cs) 2005-04-13
EP1019499B1 (en) 2008-09-10
JP2001519148A (ja) 2001-10-23
BR9812717A (pt) 2000-08-22
BR9812717B1 (pt) 2011-06-28
NO20001684L (no) 2000-06-02
HUP0003745A3 (en) 2002-04-29
NO328470B1 (no) 2010-02-22
CA2308124A1 (en) 1999-04-15
CZ20001201A3 (cs) 2000-09-13
NO20093194L (no) 2000-06-02
PL339949A1 (en) 2001-01-15
DE69840001D1 (de) 2008-10-23
JP5153031B2 (ja) 2013-02-27
AU9457198A (en) 1999-04-27
AU755774B2 (en) 2002-12-19
IL135430A0 (en) 2001-05-20
WO1999018195A2 (en) 1999-04-15
KR20010030912A (ko) 2001-04-16
EP1019499A2 (en) 2000-07-19
JP2008136480A (ja) 2008-06-19
KR100524262B1 (ko) 2005-10-28
JP2006304801A (ja) 2006-11-09
CA2308124C (en) 2008-07-08
US6306833B1 (en) 2001-10-23
NO20001684D0 (no) 2000-03-31
US6087164A (en) 2000-07-11

Similar Documents

Publication Publication Date Title
HUP0003745A2 (hu) Eljárások és készítmények tumorspecifikus citotoxicitás indukálására
WO2001014579A3 (en) Compositions and methods for delivery of an agent using attenuated salmonella containing phage
EP1173460A4 (en) PREPARATIONS AND METHODS FOR USE IN RECOMBINATORY CLONING OF NUCLEIC ACIDS
KR970000808B1 (en) Human proapolipoprotein a-1 expression
HK1030019A1 (en) Recombinational cloning using nucleic acids havingrecombination sites
AU6871398A (en) Method for enhancing expression of a foreign or endogenous gene product in pla nts
NZ312332A (en) Recombinational cloning using engineered recombination sites
HUP0102844A2 (hu) Deszaturáz-gének kukorica lipidösszetételének megváltoztatására
NZ504367A (en) Vector for tissue-specific replication and gene expression
HK1024714A1 (en) Dumbbell expression constructs for gene therapy
EP0939621A4 (en) INHIBITION OF BCL-2 PROTEIN EXPRESSION BY LIPOSOMAL ANTISENSE OLIGODE OXYNUCLEOTIDE
IL67053A (en) Method for inhibiting protein expression using complementary oligonucleotides
IL75963A0 (en) Interferon derivatives,their preparation and pharmaceutical compositions containing them
AU7154901A (en) Replication deficient adenoviral tnf vector
EP0804613A4 (en) TUMOR SUPPRESSORGENES, PROTEINS CODED BY THEM AND THE USE OF SUCH GENES AND PROTEINS
ZA959416B (en) Carrier protein having an adjuvant effect immunogenic complex containing it process for their preparation nuclofotide sequence and vaccine
WO2002022175A3 (en) Method and composition for treating tumors by selective induction of apoptosis
DE3381813D1 (en) Expressionsvektoren.
PL313445A1 (en) Grb3-3 gene, variants thereof and their use
MX2022001859A (es) Metodo para el tratamiento de la distrofia muscular al fijar como blanco el gen lama1.
WO2002004664A3 (de) Aus tumorzellen isolierbare gene mit kodierenden mononucleotid- oder dinucleotid-mikrosatelliten
FR2556365B1 (fr) Vecteurs de clonage et d'expression de l'interferon-g, bacteries transformees et procede de preparation de l'interferon-g
EP0422217A4 (en) Human recombinant placental ribonuclease inhibitor and method of production
AU6328598A (en) Modified protein kinase a-specific oligonucleotides and methods of their use